Literature DB >> 31064777

Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models.

Huizhong Xiong1, Stephanie Mittman1, Ryan Rodriguez1, Patricia Pacheco-Sanchez1, Marina Moskalenko1, Yagai Yang1, Justin Elstrott2, Alex T Ritter3, Sören Müller4, Dorothee Nickles4, Teresita L Arenzana3, Aude-Hélène Capietto3, Lélia Delamarre3, Zora Modrusan5, Sascha Rutz3, Ira Mellman3, Rafael Cubas6.   

Abstract

Exhausted T cells have been described in cancer patients and murine tumor models largely based on their expression of various inhibitory receptors. Understanding of the functional attributes of these cells is limited. Here, we report that among CD8+ T cells in commonly used syngeneic tumor models, the coexpression of inhibitory receptors PD-1, LAG3, and TIM3 defined a group of highly activated and functional effector cells. Coexpression of these receptors further enriched for antigen-specific cells with increased T-cell receptor clonality. Anti-PD-L1 treatment increased the number and activation of these triple-positive CD8+ T cells without affecting the density of PD-1- cells. The intratumoral density of CD8+ T cells coexpressing inhibitory receptors negatively correlated with tumor burden. The density ratio and pretreatment phenotype of CD8+ T cells coexpressing inhibitory receptors was positively correlated with response across a variety of tumor models. Our results demonstrate that coexpression of inhibitory receptors is not a signifier of exhausted T cells, but rather can define a group of activated and functional effector cells in syngeneic tumor models. In the cancer setting, these cells could represent a heterogeneous population of not only exhausted but also highly activated cells responsive to treatment. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31064777     DOI: 10.1158/2326-6066.CIR-18-0750

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  18 in total

1.  PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.

Authors:  Soyoung A Oh; Dai-Chen Wu; Jeanne Cheung; Armando Navarro; Huizhong Xiong; Rafael Cubas; Klara Totpal; Henry Chiu; Yan Wu; Laetitia Comps-Agrar; Andrew M Leader; Miriam Merad; Merone Roose-Germa; Soren Warming; Minhong Yan; Jeong M Kim; Sascha Rutz; Ira Mellman
Journal:  Nat Cancer       Date:  2020-06-22

2.  Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Authors:  Jaikumar Duraiswamy; Riccardo Turrini; Aspram Minasyan; David Barras; Isaac Crespo; Alizée J Grimm; Julia Casado; Raphael Genolet; Fabrizio Benedetti; Alexandre Wicky; Kalliopi Ioannidou; Wilson Castro; Christopher Neal; Amandine Moriot; Stéphanie Renaud-Tissot; Victor Anstett; Noémie Fahr; Janos L Tanyi; Monika A Eiva; Connor A Jacobson; Kathleen T Montone; Marie Christine Wulff Westergaard; Inge Marie Svane; Lana E Kandalaft; Mauro Delorenzi; Peter K Sorger; Anniina Färkkilä; Olivier Michielin; Vincent Zoete; Santiago J Carmona; Periklis G Foukas; Daniel J Powell; Sylvie Rusakiewicz; Marie-Agnès Doucey; Denarda Dangaj Laniti; George Coukos
Journal:  Cancer Cell       Date:  2021-11-04       Impact factor: 31.743

3.  LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.

Authors:  Ying Liu; Xinhong Guo; Lingbo Zhan; Lei Wang; Xinyou Wang; Ming Jiang
Journal:  Comput Math Methods Med       Date:  2021-08-12       Impact factor: 2.238

4.  Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.

Authors:  Maria-Luisa Del Rio; Jose-Antonio Perez-Simon; Jose-Ignacio Rodriguez-Barbosa
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

5.  NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division.

Authors:  Linda Borst; Marjolein Sluijter; Gregor Sturm; Pornpimol Charoentong; Saskia J Santegoets; Mandy van Gulijk; Marit J van Elsas; Christianne Groeneveldt; Nadine van Montfoort; Francesca Finotello; Zlatko Trajanoski; Szymon M Kiełbasa; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Int J Cancer       Date:  2021-11-10       Impact factor: 7.316

6.  Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment.

Authors:  Oksana Sulaieva; Olena Chernenko; Oleksiy Selesnov; Oleksandr Nechay; Oleksandr Maievskyi; Tetyana Falalyeyeva; Nazarii Kobyliak; Olena Tsyryuk; Yurii Penchuk; Dmytro Shapochka
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

7.  A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.

Authors:  Elena Tondini; Tsolere Arakelian; Koen Oosterhuis; Marcel Camps; Suzanne van Duikeren; Wanda Han; Ramon Arens; Gerben Zondag; Jeroen van Bergen; Ferry Ossendorp
Journal:  Oncoimmunology       Date:  2019-09-02       Impact factor: 8.110

8.  Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq.

Authors:  Santiago J Carmona; Imran Siddiqui; Mariia Bilous; Werner Held; David Gfeller
Journal:  Oncoimmunology       Date:  2020-03-12       Impact factor: 8.110

9.  T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

Authors:  Keyi Jia; Yayi He; Rafal Dziadziuszko; Sha Zhao; Xiaoshen Zhang; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou; Hui Yu; Liping Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-12

10.  Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.

Authors:  Rafael Cubas; Zia Khan; Qian Gong; Marina Moskalenko; Huizhong Xiong; Qinglin Ou; Christine Pai; Ryan Rodriguez; Jeanne Cheung; Andrew C Chan
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.